GATEWAY 2026
Threehorizons.
One company,
three doors.
Your bridge between the world and Japan's pharmaceutical & health industry.
5+
COUNTRIES
7+
PARTNERS
2023
FOUNDED
3
DOORS
Care Link
Specialty Pharma × Last Mile
Delivering directly to patients
Last-mile delivery of specialty pharmaceuticals from pharmacies to patient homes. End-to-end cold chain management, adherence monitoring, and PSP integration.
Global Bridge
Import × Export
A two-way bridge between Japan and the world
Japan market entry for overseas pharma and raw materials. Global expansion for Japanese OTC and supplements. Regulatory to logistics, end-to-end.
garden
Supplement Development
From idea to product
Supplement and health food planning to manufacturing. OEM/ODM, raw material sourcing, and branding support.
Latest Insights
Healthcare insights shared by CEO Masaya Yamamoto on NewsPicks
社会保障138兆円 ― コスト削減より「医療需要を減らす投資」へ
More important than the headline figure of ¥138 trillion in social security spending is what lies beneath it. On top of natural growth driven by an aging population, rising medical costs from advanced treatments and high-priced drugs will keep upward pressure relentless. Simply cutting benefits or raising premiums cannot secure long-term sustainability, given the limits on the working-age population's burden. What is needed is a strategic shift toward investments that reduce medical demand in the first place—preventive care, extending healthy life expectancy, healthcare DX for efficiency gains, and preventing disease progression. Whether Japan can redesign social security not as a cost but as an investment in people is, I believe, a question directly tied to the country's broader competitiveness.
マイナ保険証移行 ― 移行率より「受診機会の確保」で評価を
What ends this month is not the health insurance card itself, but the provisional measure that allowed expired cards to be accepted at medical institutions. From August onward, either a My Number health insurance card or a Certificate of Eligibility will be required. While online eligibility verification is taking hold in clinical settings—bringing real benefits such as prevention of duplicate prescriptions and better sharing of medical information—ongoing challenges remain: expired digital certificates, forgotten cards, and adequate support for elderly and digitally disadvantaged individuals. The success of this transition should be measured not by the My Number health insurance card adoption rate, but by whether the system can be operated in a way that leaves no one without access to medical care. Since a Certificate of Eligibility will be issued to those who choose not to use the My Number card, thorough public awareness of that option is also essential.
処方薬不正流通の抑止 ― データ横断監視で適正使用と両立を
The fraudulent diversion of prescription drugs through the public assistance system is a serious issue that undermines trust in the program itself. At the same time, it would be counterproductive if such cases led to overly restrictive access for patients who genuinely need medication. What matters is not simply tightening the rules, but building a framework that uses data to detect high-risk prescription patterns at an early stage. If cross-sectional monitoring leveraging electronic prescriptions, My Number health insurance cards, and claims data moves forward, we can expect both deterrence of illicit diversion and proper medication use. What is needed is a collaborative structure involving healthcare, social welfare, and law enforcement—one that protects those who truly need support while precisely targeting and preventing abuse of the system.